Accelerate Diagnostics To Present At The J.P. Morgan 34th Annual Healthcare Conference On January 12th
TUCSON, Ariz., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced today that Lawrence Mehren, President and Chief Executive Officer, is scheduled to present at the J.P. Morgan 34th Annual Healthcare Conference in San Francisco, CA on Tuesday, January 12th at 7:30 AM PST / 10:30 AM EST.
A live audio webcast of the presentation will be accessible from the investor portal of the company’s website at http://ir.axdx.com/.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. The company's investigational ID/AST platform utilizes proprietary molecular and phenotypic detection technologies which have the potential to significantly decrease the time to result while achieving high sensitivity and specificity.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company’s expectations regarding its anticipated launch of an FDA-cleared product, the potential of the ID/AST System and Blood Culture Assay Kit, and the company’s prospects for future growth. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 26, 2015. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
CONTACT Media Contact: Andrew Chasteen Marketing and Communications 520.404.0809 Investor Contact: Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 4